[go: up one dir, main page]

MX2012012032A - Inhibidores de la actividad de la proteina tirosina quinasa. - Google Patents

Inhibidores de la actividad de la proteina tirosina quinasa.

Info

Publication number
MX2012012032A
MX2012012032A MX2012012032A MX2012012032A MX2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A
Authority
MX
Mexico
Prior art keywords
activity
protein
inhibitors
compounds
inhibition
Prior art date
Application number
MX2012012032A
Other languages
English (en)
Inventor
Norifumi Sato
Lijie Zhan
Stephen William Claridge
Franck Raeppel
Arkadii Vaisburg
Michael Mannion
Frederic Gaudette
Masashi Kishida
Yohei Yuki
Stephene Raeppel
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MX2012012032A publication Critical patent/MX2012012032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa; En particular, la invención se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa de los receptores de los factores de crecimiento, lo que da como resultado la inhibición de la señalización del receptor, por ejemplo, la inhibición de la señalización del receptor del VEGF (factor de crecimiento endotelial vascular); La invención también proporciona compuestos, composiciones y métodos para el tratamiento de enfermedades y condiciones de proliferación de células y enfermedades, desordenes o condiciones oftálmicas.
MX2012012032A 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa. MX2012012032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
MX2012012032A true MX2012012032A (es) 2012-12-17

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012031A MX2012012031A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
MX2012012032A MX2012012032A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012012031A MX2012012031A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.

Country Status (19)

Country Link
US (3) US8455484B2 (es)
EP (2) EP2563795A4 (es)
JP (2) JP2013525286A (es)
KR (2) KR20130058006A (es)
CN (2) CN103025740B (es)
AR (2) AR080875A1 (es)
AU (2) AU2011241420B2 (es)
CA (2) CA2796054A1 (es)
CO (2) CO6630193A2 (es)
EA (2) EA201291052A1 (es)
MX (2) MX2012012031A (es)
MY (1) MY157319A (es)
NZ (2) NZ602948A (es)
PH (2) PH12012502073A1 (es)
SG (2) SG184883A1 (es)
TW (2) TW201204735A (es)
UA (1) UA108878C2 (es)
WO (2) WO2011127567A1 (es)
ZA (2) ZA201207482B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002427A (es) * 2007-08-29 2010-03-30 Methylgene Inc Inhibidores de actividad de la proteina tirosina cinasa.
AR070539A1 (es) * 2008-03-05 2010-04-14 Methylgene Inc Inhibidores de la actividad de proteina tirosina quinasa
JP2013525286A (ja) * 2010-04-16 2013-06-20 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
BRPI0513982A (pt) * 2004-07-30 2007-11-27 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
CA2608726C (en) * 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
MX2010002427A (es) * 2007-08-29 2010-03-30 Methylgene Inc Inhibidores de actividad de la proteina tirosina cinasa.
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
AR070539A1 (es) * 2008-03-05 2010-04-14 Methylgene Inc Inhibidores de la actividad de proteina tirosina quinasa
JP2013525286A (ja) * 2010-04-16 2013-06-20 メチルジーン・インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
AU2011241422B2 (en) 2015-05-07
AR080871A1 (es) 2012-05-16
US20140315801A1 (en) 2014-10-23
PH12012502070A1 (en) 2015-05-08
ZA201207482B (en) 2013-09-25
EP2563795A1 (en) 2013-03-06
US20110257100A1 (en) 2011-10-20
TW201204734A (en) 2012-02-01
SG184883A1 (en) 2012-11-29
CA2796008A1 (en) 2011-10-20
US8906852B2 (en) 2014-12-09
SG184882A1 (en) 2012-11-29
EA201291052A1 (ru) 2013-04-30
AR080875A1 (es) 2012-05-16
CA2796054A1 (en) 2011-10-20
CO6630193A2 (es) 2013-03-01
CO6640224A2 (es) 2013-03-22
CN103025740A (zh) 2013-04-03
JP2013525286A (ja) 2013-06-20
NZ602948A (en) 2014-09-26
JP2013523846A (ja) 2013-06-17
US8455484B2 (en) 2013-06-04
NZ602954A (en) 2014-11-28
UA108878C2 (ru) 2015-06-25
ZA201207557B (en) 2013-06-26
MX2012012031A (es) 2012-12-17
EA201291055A1 (ru) 2013-09-30
CN103025740B (zh) 2015-07-01
KR20130058006A (ko) 2013-06-03
WO2011127567A1 (en) 2011-10-20
WO2011127565A1 (en) 2011-10-20
US20110257175A1 (en) 2011-10-20
TW201204735A (en) 2012-02-01
EP2563794A1 (en) 2013-03-06
AU2011241420B2 (en) 2015-04-16
AU2011241422A1 (en) 2012-11-01
MY157319A (en) 2016-05-31
EP2563794A4 (en) 2013-12-04
KR20130100234A (ko) 2013-09-10
EP2563795A4 (en) 2013-10-23
CN102947315A (zh) 2013-02-27
PH12012502073A1 (en) 2013-02-11

Similar Documents

Publication Publication Date Title
MX2012012032A (es) Inhibidores de la actividad de la proteina tirosina quinasa.
CO6290684A2 (es) Inhibidores de actividad de proteina tirosina quinasa
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
MX375194B (es) Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
MX383140B (es) Heterociclos bicíclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4).
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CR20150490A (es) Derivados de piridina como inhibidores de la quinasa reorganizada durante la transfección (ret)
CL2022000998A1 (es) Inhibidores de las cinasas raf
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
MX2017014375A (es) Moduladores del ccr2.
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
MX2010001813A (es) Metodos y composiciones para el tratamiento de canceres.
CR20150029A (es) Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular

Legal Events

Date Code Title Description
FA Abandonment or withdrawal